Why the study?
Dyslipidemia is associated with cardiovascular disease risk, but its effects on cardiometabolic health in relatively young, healthy adults required evaluation.
Does dyslipidemia worsen cardiometabolic health and increase CVD risk in relatively young, otherwise healthy adults?
Does dyslipidemia worsen cardiometabolic health and increase CVD risk in relatively young, otherwise healthy adults?
Dyslipidemia in relatively young, otherwise healthy adults is associated with adverse cardiometabolic changes and significantly increased 10-year CVD risk.
Dyslipidemia was associated with higher 10-year CVD risk in young adults; leaves open whether screening or treatment alters outcomes.
Dyslipidemia, abnormal levels of lipids in the bloodstream, is associated with cardiovascular disease risk (CVD). The purpose of this study was to evaluate the effects of dyslipidemia on cardiometabolic health in relatively young, healthy adults. Participants were 54 healthy males and females aged 18-60 years. Participants were assessed for anthropometrics, body composition, blood pressure and vascular stiffness indicators, microvascular health, and glucose and lipid levels. Using a cross-sectional approach, participants were characterized and grouped as having dyslipidemia or not, and then statistically assessed to determine whether differences in other cardiometabolic health measures existed between the groups. There were significant differences between groups for body weight and composition (total mass, muscle mass, visceral fat, bone mass, and body mass index, all, p < 0.027, Cohen's d > 0.605) with the dyslipidemia group being higher. There were significant differences between groups for peripheral and central blood pressures (all, p < 0.003, Cohen's d > 0.899), as well as for vascular stiffness indicators (pulse pressure, augmentation pressure, augmentation index, augmentation index 75) (all, p < 0.022, Cohen's d > 0.672) with elevations noted in the dyslipidemia group. Ten-year CVD risk was significantly different between groups, with an average risk of 0.8% in the normal lipids group and a risk of 5.4% in the dyslipidemia group (p < 0.001, Cohen's d = 1.260). However, there were no significant differences in macro- or micronutrient intake between groups (all, p > 0.166, Cohen's d < 0.412). There is a significant impact on cardiometabolic health in individuals with dyslipidemia who are otherwise healthy, which may increase individual risk for CVD. Trial Registration: ClinicalTrials.gov identifier: NCT06544915.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: